US28658R1068 - Common Stock
Eliem Therapeutics just reported results for the first quarter of 2024.
/PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders....
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have...
Eliem Therapeutics just reported results for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eliem Therapeutics (NASDAQ:ELYM) just reported results for the fourth quarter o...
It's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers for Friday!
BioSig Technologies (BSGM) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia's (NVDA) Inception program.
Discover Financial (DFS) stock is falling on Thursday after the financial services company revealed it's undergoing a regulatory review.
Netcapital (NCPL) stock is dropping on Thursday after the fintech company announced the pricing of a public share offering.
Eliem Therapeutics (ELYM) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives.
It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Thursday morning!
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a...
Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed...
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization...